August 2, 2018 06:52 AM EDTUpdated 07:15 AM

Can two old drugs — including an Eli Lilly flop — make one good treatment for Alzheimer’s? Karuna has $42M to find out

John Carroll

Editor & Founder

Back when Steven Paul was a star CNS researcher who had jumped to industry at Eli Lilly back in ’93, he boasted of a broad …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

As a challenging first half nears a close, biopharma uncertainty persists

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation